Comparative Pharmacology
Head-to-head clinical analysis: AMINOPHYLLINE DYE FREE versus TRUPHYLLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOPHYLLINE DYE FREE versus TRUPHYLLINE.
AMINOPHYLLINE DYE FREE vs TRUPHYLLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular cAMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.
Truphylline is a xanthine derivative that inhibits phosphodiesterase (PDE) and blocks adenosine receptors, leading to bronchodilation, increased respiratory drive, and anti-inflammatory effects.
Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).
Aminophylline 5-6 mg/kg IV loading dose over 20-30 minutes, then 0.5-0.7 mg/kg/h continuous IV infusion; theophylline 300-600 mg PO daily divided q6-12h, titrated to serum theophylline level of 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life is approximately 7-9 hours in healthy adults. In smokers, half-life decreases to 4-5 hours. In patients with hepatic cirrhosis, heart failure, or COPD, half-life may prolong to 20-30 hours.
Terminal half-life: adults 6-8 hours, children 3-5 hours, neonates 24+ hours. Prolonged in hepatic or cardiac impairment.
Primarily hepatic metabolism (approximately 90%) to 1,3-dimethyluric acid and other metabolites; renal excretion of unchanged drug accounts for about 10-13% of the dose. Less than 1% is excreted via bile or feces.
Renal excretion of unchanged drug (80-90%) and metabolites; biliary/fecal elimination <10%.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator